Testing VAS-101 for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This early-phase trial tests a new drug called VAS-101 for people with sickle cell disease. It aims to find a safe dose and see how the drug affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have a confirmed diagnosis of sickle cell disease (like HbSS, HbSC, HbSβ⁺, or HbSβ⁰).
- You have not had a blood transfusion in the last 60 days.
- You have not had a sickle cell pain crisis needing treatment in the last 14 days, and you have had fewer than three such crises in the past year.
- Your liver and kidney function tests are within certain limits, and your hemoglobin level is at least 7 g/dL.
- If you take hydroxyurea, L-glutamine, or crizanlizumab, your dose has been stable for at least 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
This study looks at how major organs like the brain, kidneys, heart, and liver are affected in adults with sickle cell disease, whether they've had a bone marrow transplant or gene therapy, or are continuing regular treatment. You'll get detailed tests that can help doctors understand the disease better, which may lead to improved care.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
This trial tests a gene therapy that uses a modified virus to deliver a healthy gene to your blood stem cells. It aims to help people with sickle cell disease produce normal red blood cells and reduce painful crises.
Hear when a new Sickle Cell Disease, Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.